Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: ion channel modulators - Bristol-Myers Squibb/Icagen

Drug Profile

Research programme: ion channel modulators - Bristol-Myers Squibb/Icagen

Alternative Names: Atrial fibrillation therapy - Icagen

Latest Information Update: 11 Feb 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Icagen
  • Developer Bristol-Myers Squibb; Icagen
  • Class Small molecules
  • Mechanism of Action Ion channel modulators; Potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atrial fibrillation

Most Recent Events

  • 08 Aug 2007 Bristol-Myers Squibb discontinues its development in this research programme
  • 10 Aug 2006 Preclinical trials in Atrial fibrillation in USA (unspecified route)
  • 21 Nov 2005 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top